OR for progression of radiographic sacroiliitis by at least one grade in the opinion of both readers over 2 years in patients with axial spondyloarthritis, univariate analysis
| Non-radiographic axial spondyloarthritis (n=95) | AS (n=94)* | All patients (n=189*) | ||||
|---|---|---|---|---|---|---|
| Parameters at baseline | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value |
| Sex, (male vs female) | 0.10 (0.01 to 0.82) | 0.032 | 3.15 (0.63 to 15.73) | 0.162 | 0.58 (0.24 to 1.73) | 0.212 |
| HLA-B27 (positive vs negative) | 0.76 (0.24 to 2.45) | 0.640 | 1.80 (0.21 to 15.36) | 0.591 | 0.89 (0.33 to 2.38) | 0.809 |
| CRP (>6 mg/l vs ≤6 mg/l) | 3.65 (1.19 to 11.15) | 0.023 | 5.08 (1.02 to 25.38) | 0.048 | 3.23 (1.37 to 7.59) | 0.007 |
| ESR (>20 mm/h vs ≤20 mm/h) | 1.59 (0.44 to 5.72) | 0.478 | 2.42 (0.64 to 9.12) | 0.193 | 1.72 (0.71 to 4.17) | 0.233 |
| Duration of symptoms (>5 vs ≤5 years) | – | – | 3.11 (0.75 to 12.87) | 0.117 | 1.45 (0.62 to 3.43) | 0.392 |
| Peripheral arthritis (present vs not present) | 0.66 (0.14 to 3.25) | 0.613 | 0.67 (0.08 to 5.75) | 0.712 | 0.69 (0.19 to 2.46) | 0.564 |
| Uveitis ever (present vs not present) | 0.73 (0.15 to 3.58) | 0.693 | 0.36 (0.04 to 2.98) | 0.340 | 0.51 (0.15 to 1.82) | 0.301 |
| Therapy with DMARD (present vs not present) | 0.52 (0.14 to 2.00) | 0.344 | 0.20 (0.02 to 1.65) | 0.134 | 0.36 (0.12 to 1.11) | 0.076 |
↵* Patients with complete ankylosis of sacroiliac joints were excluded.
AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27.